69 results about "Bacterial prostatitis" patented technology

A composition and a method for treatment of prostate related dysfunction and, particularly, non-bacterial prostatitis and, even more particularly, non-bacterial chronic prostatitis. The composition primarily relies upon the use of a bioflavonoid and, particularly, that bioflavonoid known as quercetin. The quercetin is mixed with a proteolytic digestive enzyme protease, such as bromelin and papain, as the primary active ingredients. However, the composition may optionally and beneficially include other prostatitis affecting agents, such as zinc derived from zinc gluconate, cranberry, saw palmetto, as well as some other active and non-active ingredients.

A depressant of capsaicin-sensitive sensory nerve, containing quinuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a salt thereof as an active ingredient, specifically a therapeutic drug of interstitial cystitis, hypersensitive disorder of the lower urinary tract, and / or abacterial prostatitis.

A composition and a method for treatment of prostate related dysfunction and, particularly, non-bacterial prostatitis and, even more particularly, non-bacterial chronic prostatitis. The composition primarily relies upon the use of a bioflavonoid and, particularly, that bioflavonoid known as quercetin. The quercetin is mixed with a proteolytic digestive enzyme protease, such as bromelin and papain, as the primary active ingredients. However, the composition may optionally and beneficially include other prostatitis affecting agents, such as zinc derived from zinc gluconate, cranberry, saw palmetto, as well as some other active and non-active ingredients.

A depressant of capsaicin-sensitive sensory nerve, containing quinuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate or a salt thereof as an active ingredient, specifically a therapeutic drug of interstitial cystitis, hypersensitive disorder of the lower urinary tract, and / or abacterial prostatitis.

A method for treatment or prevention of chronic nonbacterial prostatitis in individuals without urethral sphincter dysfunction, comprises administering an effective amount of (i) a selective estrogen receptor modulator (SERM) having estrogen antagonist effect in the prostate, (ii) an aromatase inhibitor, and / or (iii) an antiestrogen.

Disclosed is a compound useful as an active ingredient for a pharmaceutical composition for treating FAAH-related diseases. Extensive studies have been made on compounds having an FAAH-inhibiting activity, and it is confirmed that a piperazine-1-carboxylate compound having a benzimidazol-2-ylcarbonyl, a benzofuran-2-ylcarbonyl or the like bound to position-4 in the piperazine moiety has an excellent FAAH-inhibiting activity and has an activity to increase the effective bladder capacity, an activity to ameliorate sleep disorder, an anti-diuretic activity and an analgesic activity on lower urinary tract pain including bladder pain. The carbamate compound has an excellent FAAH-inhibiting activity and can be used as a prophylactic and / or therapeutic agent for FAAH-related diseases, particularly nycturia, interstitial cystitis, painful bladder syndrome or chronic non-bacterial prostatitis / chronic pelvic pain syndrome.

A method for preparing ofloxacin sustained-release capsules comprises steps of preparing materials, mixing, preparing pills, coating and filling into capsules. In the coating process, granules do not easily fall off and coating liquid is easily attached so that sustained-release function can be achieved and medicine can be relatively well released. By employing the ofloxacin sustained-release capsules prepared by the method, experiments show that, absorption in vivo is slowed down, shape of a blood concentration-time curve becomes relatively flat, sudden release is avoided, and the ofloxacin sustained-release capsules can keep blood concentration remarkably superior to the conventional ofloxacin tablets and has sustained-release function. The ofloxacin sustained-release capsules are used for treating adult sensitive strain-induced urinary tract infections and genitourinary tract infections comprising simple urinary tract infections, complex urinary tract infections, bacterial prostatitis, gonococcal urethritis, cervicitis, intrauterine infections, appendagitis, etc.

The invention provides an extract of total flavonoids of coromandel coast falsemallow. The weight percent content of the total flavonoids is no less than 1% by taking the weight percent of rutin as a reference. The invention further provides a preparation method and an application of the extract. The extract is stable and controllable in quality as well as simple and feasible in extraction process and cannot perform pollution on the environment, thereby being suitable for large-scale extraction. The extract is used for treating prostatic diseases, and particularly has definite and safe medicinal effects for treating prostatic hyperplasia, prostatitis, prostatic cancers and abacterial prostatitis, thereby providing a new medicine selection for clinical applications.

The invention discloses an extract of diterpene-containing white flower cacalia seeds, an extracting method of the extract and an application of the extract. The extracting method includes the steps: drying the white flower cacalia seeds, crushing, sieving, extracting by alcoholic solution, and filtering to obtain total white flower cacalia seed alcohol extracting solution; performing decompression and concentration for the total white flower cacalia seed alcohol extracting solution to constant weight to obtain paste; sequentially extracting by cyclohexane and ethyl acetate to obtain an ethyl acetate extract. The ethyl acetate extract is the diterpene-containing white flower cacalia seed extract. The extract verifies that the extract of the white flower cacalia seeds containing ditepenoid compounds has good function of resisting chronic nonbacterial prostatitis. The white flower cacalia seeds are wide in distribution and easily obtained, the extract of the diterpene-containing white flower cacalia seeds is applied to preparation of medicines for preventing and treating chronic prostatitis, and a preparation method is simple and low in cost and meets development requirements of the medicines.

The invention provides a traditional Chinese medicine mixture for treating non-bacterial prostatitis. The traditional Chinese medicine mixture is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 5-10 parts of cassia twig, 1-5 parts of asarum, 10-25 parts of yam rhizome, 5-10 parts of lindera aggregata, 8-15 parts of fennel, 10-25 parts of beautiful sweetgum fruit, 10-25 parts of salvia miltiorrhiza, 15-30 parts of tangerine seed, 3-8 parts of rhizoma anemarrhenae, 3-10 parts of cortex phellodendri, 15-30 parts of prepared fleece flower root, 10-25 parts of dogwood, 5-15 parts of radix rehmanniae, 5-15 parts of radix rehmanniae preparata, 10-25 parts of calamus, 10-30 parts of poria cocos, 10-25 parts of alisma, 10-25 parts of cortex moutan, 5-15 parts of rhizoma cimicifugae, 10-25 parts of radix achyranthis bidentatae and 5-10 parts of licorice. All the medicines of the traditional Chinese medicine mixture are compatible with each other and complement each other; the traditional Chinese medicine mixture has the effects of clearing away heat and toxic materials, resisting bacteria, eliminating inflammation, activating blood circulation to dissipate blood stasis, replenishing blood, nourishing yin, promoting qi circulation, relieving pain, clearing damp, promoting diuresis, activating blood to promote menstruation, dissolving lumps, resolving masses and tonifying kidney to control nocturnal emission and the like. All the medicines of the traditional Chinese medicine mixture have synergistic effects. When being used for treating non-bacterial prostatitis, the traditional Chinese medicine mixture has the characteristics of treating both manifestation and root causes of diseases, having an obvious curative effect, being low in treatment cost, having no toxic or side effect and the like.

The invention discloses an application of quercetin in preparation of a drug for treating CP (chronic prostatitis) and a drug which is used for treating nonbacterial prostatitis and has the active component of quercetin. It is found that the quercetin can reduce the prostate index and reduce infiltration of inflammatory cells in prostate mesenchyme on the premise that the body weight is not affected, which indicates that the quercetin has the significant inhibition effect on the CP in histology; the quercetin can significantly reduce levels of inflammatory cell factors IL-1beta, IL-2, IL-6 andTNF-alpha in prostatitis tissue, which proves that the quercetin has the significant anti-inflammatory function on the CP; the quercetin can significantly improve antioxidant enzyme activity in bodies and reduce production of oxidative stress products, which indicates that the quercetin has the significant antioxidation effect on the CP. The results prove that the quercetin has significant treatment effects on the CP, and the foundation is laid for development of clinical drugs.

The present invention relates to the association between detecting and quantifying the presence of macrophage migration inhibitory factor (MIF) in urine, bladder and prostate tissues for the purpose of diagnosis and prognosis of urological inflammatory. In addition, methods to inactivate MIF activity by use of antibodies or specific MIF inhibitors can be used to treat these diseases. For instance, such diseases as chronic pelvic pain syndrome, non-bacterial prostatitis, and interstitial cystitis may be mediated by MIF release. Periodic assays for MIF could be conducted for a patient to determine if the patient's MIF urine levels are high or increasing. In addition, intravesical MIF antibodies or other MIF-specific inhibitors would reduce or ameliorate these pelvic diseases.

Disclosed is a prophylactic or therapeutic agent for diseases associated with pains in urinary organs. It is confirmed that a pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate compound or a salt thereof has an effective bladder capacity increasing activity and also has an analgesic activity on pains in the bladder and the testis, which rely on a FAAH inhibiting activity thereof. Therefore, a pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate compound or a salt thereof can be used for the prevention or treatment of interstitial cystitis / bladder pain syndrome and / or chronic non-bacterial prostatitis / chronic pelvic pain syndrome.